Section Arrow
CABA.NASDAQ
- Cabaletta Bio
Quotes are at least 15-min delayed:2026/04/09 19:27 EDT
After Hours
Last
 3.138
-0.032 (-1.01%)
Bid
3.1
Ask
3.14
High 3.17 
Low 3.13 
Volume 21.44K 
Regular Hours (Closed)
Last
 3.17
+0.08 (+2.59%)
Day High 
3.22 
Prev. Close
3.09 
1-M High
3.54 
Volume 
1.90M 
Bid
3.1
Ask
3.14
Day Low
3.04 
Open
3.07 
1-M Low
2.45 
Market Cap 
343.99M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.83 
20-SMA 2.93 
50-SMA 2.94 
52-W High 3.78 
52-W Low 1.06 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.10/-1.48
Enterprise Value
346.87M
Balance Sheet
Book Value Per Share
1.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ONCOOnconetix Inc.1.22+0.09+7.96%0PE
After Hours 1.15 -0.07 -5.74%
GLMDGalmed Pharmaceuticals Ltd0.7852+0.16275+26.15%-- 
After Hours 0.7739 -0.0113 -1.44%
QNCXQuince Therapeutics0.1237-0.0594-32.44%-- 
After Hours 0.1194 -0.0043 -3.48%
ELABPmgc Holdings Inc5.26+0.76+16.89%0PE
After Hours 5.42 +0.16 +3.04%
IOVAIovance Biotherapeutics4.01+0.54+15.56%-- 
After Hours 3.9701 -0.0399 -1.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel(resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.